Cleared Traditional

INNOVANCE Free PS Ag (K181525) - FDA 510(k) Clearance

Class II Hematology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K181525 · Siemens Healthcare Diagnostics Products GmbH · Hematology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 2018
Decision
88d
Days
Class 2
Risk

K181525 is an FDA 510(k) clearance for the INNOVANCE Free PS Ag. Classified as Test, Qualitative And Quantitative Factor Deficiency (product code GGP), Class II - Special Controls.

Submitted by Siemens Healthcare Diagnostics Products GmbH (Marburg, DE). The FDA issued a Cleared decision on September 7, 2018 after a review of 88 days - a notably fast clearance cycle.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.7290 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Siemens Healthcare Diagnostics Products GmbH devices

Submission Details

510(k) Number K181525 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 11, 2018
Decision Date September 07, 2018
Days to Decision 88 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
25d faster than avg
Panel avg: 113d · This submission: 88d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code GGP Test, Qualitative And Quantitative Factor Deficiency
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7290
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Hematology devices follow this clearance model.

Regulatory Peers - GGP Test, Qualitative And Quantitative Factor Deficiency

All 90
Devices cleared under the same product code (GGP) and FDA review panel - the closest regulatory comparables to K181525.
HemosIL von Willebrand Factor Antigen
K200033 · Instrumentation Laboratory CO · Aug 2020
Cryocheck Chromogenic Factor VIII
K193204 · Precision Biologic · Jul 2020
CRYOcheck FVIII Inhibitor Kit
K183440 · Precision Biologic, Inc. · Mar 2019
HEMOSIL VON WILLEBRAND ACTIVITY ASSAY
K133005 · Instrumentation Laboratory CO · Mar 2014
HEMOSIL PROTEIN S ACTIVITY ASSAY
K102164 · Instrumentation Laboratory CO · Mar 2011
HEMOSIL PROCLOT
K070635 · Instrumentation Laboratory CO · Mar 2007